Recent Updates
Recently added Catalysts
TLX Negative Sentiment

TELIX PHARMACEUTICALS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Stockholders of the Ongoing Investigation

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Telix Pharmaceuticals regarding potential violations of federal securities laws, particularly related to the company's disclosures about prostate cancer therapeutic candidates. The inquiry was prompted by the receipt of a subpoena from the U.S. Securities and Exchange Commission. Following the investigation announcement, Telix's stock price experienced a significant drop of 10.44%. Investors who have suffered losses are encouraged to discuss their legal options with the law firm.
Price reaction · baseline $10.66 (2025-10-31 close) · hit after-hours · 1 other TLX headline(s) in the window, move may be shared
day 0 close · peak
-2.5%

Market Sentiment Analysis

CONCERNS & RISKS

  • Telix is under investigation for potential violations of federal securities laws.
  • The company received a subpoena from the SEC regarding its prostate cancer therapeutic candidates.
  • Following the investigation announcement, Telix's stock price fell by 10.44%.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Telix and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Nov. 01, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ:TLX) on behalf of Telix stockholders. Our investigation concerns whether Telix has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates."
On this news, Telix's American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.
If you purchased or otherwise acquired Telix shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

Who should investors contact regarding Telix losses?

Investors affected by Telix losses should contact Brandon Walker or Marion Passmore directly.

What is the reason for the investigation into Telix?

The investigation focuses on potential violations of federal securities laws by Telix.

What happened to Telix's stock on July 22, 2025?

Telix's stock price dropped by 10.44% after disclosure of an SEC subpoena.

Is there a cost for contacting Bragar Eagel & Squire?

No, there is no cost or obligation to contact Bragar Eagel & Squire.

Where is Bragar Eagel & Squire located?

Bragar Eagel & Squire has offices in New York, South Carolina, and California.

Last updated: Nov 1, 2025